Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07355478

Asia Myelodysplastic Syndrome (MDS) Registry

The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Myelodysplastic Syndromes (MDS) Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Myelodysplastic Syndromes

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution - 0003, Singapore

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:

  • Aged at least 18 years at initial diagnosis of MDS
  • Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
  • Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate

Inclusion criteria

for the prospective enrolment of MDS participants:

  • Aged at least 18 years at initial diagnosis of MDS; and
  • Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
  • Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate

Exclusion criteria

  • None

Treatment and study plan

Prescribed treatments for myelodysplastic syndromes (MDS)

Drug

According to the product label

Primary outcomes

  1. Participant age

    Time frame: Baseline

  2. Participant sex

    Time frame: Baseline

  3. Participant race

    Time frame: Baseline

  4. Participant weight

    Time frame: Baseline

  5. Participant height

    Time frame: Baseline

  6. Participant body mass index (BMI)

    Time frame: Baseline

  7. Participant smoking status

    Time frame: Baseline

  8. Participant drinking status

    Time frame: Baseline

  9. Family history of MDS or other hematopoietic cancers

    Time frame: Baseline

  10. Participant myelodysplastic syndromes diagnosis information

    Time frame: Baseline

  11. Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis

    Time frame: Baseline

  12. Participant comorbidities at diagnosis

    Time frame: Baseline

  13. Participant Charlson comorbidity index (CCI) score at diagnosis

    Time frame: Baseline

  14. Prior clinical diagnosis of other cancers

    Time frame: Baseline

  15. Prior clinical diagnosis of hematological diseases

    Time frame: Baseline

  16. Anemia status at diagnosis

    Time frame: Bseline

  17. Thrombocytopenia status at diagnosis

    Time frame: Baseline

  18. Neutropenia status at diagnosis

    Time frame: Baseline

  19. Iron overload status at diagnosis

    Time frame: Baseline

  20. Red blood cell (RBC) transfusion dependence status at diagnosis

    Time frame: Baseline

  21. International Prognostic Scoring System (IPSS) score at diagnosis

    Time frame: Baseline

  22. Revised International Prognostic Scoring System (IPSS-R) score at diagnosis

    Time frame: Baseline

  23. Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis

    Time frame: Baseline

  24. Bone marrow aspirate results

    Time frame: Baseline and up to 2-years

  25. Presence of dysplasia

    Time frame: Baseline and up to 2-years

  26. Cytogenetic test results

    Time frame: Baseline and up to 2-years

  27. Mutation test results at diagnosis

    Time frame: Baseline

  28. Complete blood count test results at diagnosis

    Time frame: Baseline

  29. Mean corpuscular volume (MCV)

    Time frame: Baseline and up to 2-years

  30. C-reactive protein (CRP)

    Time frame: Baseline and up to 2-years

  31. Serum ferritin (SF) level

    Time frame: Baseline and up to 2-years

  32. Serum erythropoietin levels

    Time frame: Baseline and up to 2-years

  33. Lactate dehydrogenase (LDH)

    Time frame: Baseline and up to 2-years

Secondary outcomes

  1. Initial treatment received following diagnosis

    Time frame: Baseline

  2. Prior treatments and concomitant medications received

    Time frame: Baseline

  3. Subsequent treatments received

    Time frame: Up to 2-years

  4. Time from diagnosis to treatment initiation

    Time frame: Baseline

  5. Treatment duration

    Time frame: Up to 2-years

  6. Real-world overall survival (rwOS)

    Time frame: Baseline and up to 2-years

  7. Time to disease-risk progression (per IPSS-R)

    Time frame: Baseline and up to 2-years

  8. Time to acute myeloid leukemia (AML) progression

    Time frame: Baseline and up to 2-years

  9. Time to iron overload

    Time frame: Baseline and up to 2-years

  10. Overall response rate (ORR)

    Time frame: Baseline and up to 2-years

  11. Duration of response (DOR)

    Time frame: Baseline and up to 2-years

  12. Real-world relapse-free survival (rwRFS)

    Time frame: Baseline and up to 2-years

Study contacts

Contact information is provided by the study sponsor or research team.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

[email protected]

855-907-3286

First line of the email MUST contain NCT # and Site #.

CONTACT

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jan 21, 2026
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.